By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Re:Thinking with Adam GrantJohn Green on solving big medical problems | ReThinking with Adam Grant
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
John Green on tuberculosis injustice, pharma pressure, and meaning-making creativity
- Tuberculosis remains the world’s deadliest infectious disease largely because global systems do not value all human lives equally, despite the fact that TB is curable with existing tools.
- Green’s commitment deepened after meeting Henry, a TB patient in Sierra Leone, whose prolonged and difficult treatment personalized the moral urgency behind the statistics.
- Pharmaceutical incentives often misalign with public health needs, but targeted advocacy and pressure can reduce prices and expand access, as seen with the TB drug bedaquiline after patent pressure enabled generic competition.
- Public investment is irreplaceable in TB control, and interruptions in funding (e.g., treatment disruptions) can drive drug resistance and create broader societal risk.
- Green connects his creative life and mental health to his work, arguing for permission to be imperfect while creating, resisting external-validation dependence, and finding meaning through community and attention.
IDEAS WORTH REMEMBERING
5 ideasTB persists because neglect is structural, not scientific.
Green argues the central barrier isn’t a lack of cures but a lack of equal valuation of lives—TB concentrates where poverty and weak health systems limit access to tools that already exist.
Personal stories convert abstract mortality into moral urgency.
Meeting Henry in Sierra Leone—and later reconnecting—turned “1.25 million deaths” into an emotionally comprehensible reality, motivating sustained advocacy beyond awareness-raising.
TB is curable, but the cure is operationally hard.
Months-long daily combination antibiotics (and far longer regimens for drug-resistant TB) make adherence fragile; interrupted treatment can be catastrophic and accelerates resistance.
Drug resistance is not only an individual tragedy; it’s a community-level threat.
Treatment gaps increase the spread of harder-to-treat strains, raising the risk of a future TB variant with few or no effective tools—effectively “back to the 1910s.”
Market incentives reliably underdeliver for diseases of poverty.
Green highlights how profit-maximization can make low-need “lifestyle” drugs more attractive than lifesaving TB innovations, requiring public pressure and policy to correct misalignment.
WORDS WORTH SAVING
5 quotesThe short answer to why we don't cure it is that we simply have systems that don't value all human lives equally.
— John Green
What drives me absolutely bonkers is knowing that we have the ability to confront this disease and that we choose not to.
— John Green
But at any rate, that's how I think of writing, is that I'm sitting in my basement for years saying, writing some version of Marco, Marco, Marco, and, uh, eventually the book comes out and for the first time I hear someone say back to me, "Polo."
— John Green
You know, I, I've lived with, with fairly serious illness for most of my adult life, and yet I also have a really wonderful life, and those things aren't mutually exclusive at all.
— John Green
I, I think the meaning of life is to be with each other, to be in community, and to carry each other through everything in life, and I think that's why we're here.
— John Green
SPEAKERS
John Green
guestAuthor and YouTube creator (Vlogbrothers/Crash Course) known for his advocacy and writing on tuberculosis and global health.
Adam Grant
hostOrganizational psychologist and professor at Wharton, host of the podcast ReThinking.
High quality AI-generated summary created from speaker-labeled transcript.
